Live Analyst Rating Changes 35127 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Mohit Bansal
WF

Mohit Bansal

Wells Fargo
Wall Street Analyst
★★☆☆☆
#2279
on 13Foresight · ranked by our own returns
56%
Success Rate
-0.8%
Average Return
59 of 106 calls profitable · +11.7% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 56% of Mohit Bansal's ratings turned a profit when each position was held for 1 year — averaging -0.8% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

129 Buy 57 Hold 0 Sell
Mohit's Stock Coverage 34 ratings · 2026-09-28
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
BNTX
BioNTech SE
 Sep 24, 2026 BUY Strong Buy
+36.4% avg upside
26 analysts
$140.00
42.16% Upside
 +0.0% ·
AMGN
Amgen
 Sep 22, 2026 HOLD Buy
-22.6% avg upside
57 analysts
$435.00
4.87% Upside
 +1.1% ·
PFE
Pfizer
 Sep 21, 2026 HOLD Buy
+17.2% avg upside
45 analysts
$28.00
2.42% Downside
 +2.8% ·
LLY
Eli Lilly & Co
 Sep 21, 2026 BUY Strong Buy
-8.9% avg upside
49 analysts
$1330.00
12.36% Upside
 +1.6% ·
BIIB
Biogen
 Sep 18, 2026 BUY Strong Buy
+12.1% avg upside
53 analysts
$250.00
9.81% Upside
 +5.6% ·
VERA
Vera Therapeutics
 Sep 15, 2026 BUY Strong Buy
+106.9% avg upside
19 analysts
$70.00
115.17% Upside
 +1.3% ·
BMRN
BioMarin Pharmaceutical
 Sep 11, 2026 BUY Strong Buy
+59.3% avg upside
52 analysts
$80.00
32.75% Upside
 -6.6% ·
MRK
Merck & Company
 Sep 04, 2026 BUY Strong Buy
-4.9% avg upside
43 analysts
$170.00
14.25% Upside
 -0.8% ·
SMMT
Summit Therapeutics
 Aug 26, 2026 BUY Strong Buy
+87.6% avg upside
29 analysts
$30.00
92.22% Upside
 +18.8% ·
ABBV
AbbVie
 Aug 17, 2026 BUY Strong Buy
-7.9% avg upside
47 analysts
$300.00
13.46% Upside
 +6.3% ·
MIST
Milestone Pharmaceuticals
 Aug 13, 2026 BUY Strong Buy
+851.3% avg upside
8 analysts
$7.00
787.80% Upside
 -26.4% ·
REGN
Regeneron
 Aug 12, 2026 HOLD Strong Buy
+0.3% avg upside
59 analysts
$750.00
4.85% Downside
 -1.1% ·
MLYS
Mineralys Therapeutics, Inc.
 Aug 12, 2026 BUY Strong Buy
+77.0% avg upside
12 analysts
$55.00
112.66% Upside
 -0.6% ·
JAZZ
Jazz Pharmaceuticals
 Aug 10, 2026 BUY Strong Buy
+3.8% avg upside
35 analysts
$300.00
26.18% Upside
 -7.2% ·
HALO
Halozyme
 Aug 07, 2026 HOLD Buy
-42.8% avg upside
20 analysts
$95.00
16.61% Downside
 +9.0% ·
TVTX
Travere Therapeutics
 Aug 06, 2026 BUY Strong Buy
-2.1% avg upside
22 analysts
$80.00
34.65% Upside
 -4.8% ·
GILD
Gilead Sciences
 Aug 05, 2026 BUY Strong Buy
-21.6% avg upside
66 analysts
$165.00
9.36% Upside
 +14.2% ·
VRTX
Vertex Pharmaceuticals
 Aug 04, 2026 BUY Strong Buy
-15.5% avg upside
62 analysts
$550.00
4.61% Upside
 +9.9% ·
NBIX
Neurocrine
 Jul 31, 2026 BUY Strong Buy
+35.2% avg upside
37 analysts
$200.00
44.51% Upside
 -12.3% ·
BMY
Bristol-Myers Squibb
 Jul 31, 2026 HOLD Buy
-2.3% avg upside
42 analysts
$65.00
3.33% Upside
 -3.8% ·
IRWD
Ironwood Pharma
 May 05, 2026 HOLD Hold
+187.7% avg upside
23 analysts
$5.00
21.06% Upside
 -8.6% ·
WVE
Wave Life Sciences
 Apr 01, 2026 BUY Strong Buy
+450.4% avg upside
29 analysts
$13.00
243.89% Upside
 -44.7% ·
XENE
Xenon
 Aug 12, 2025 BUY Strong Buy
+52.9% avg upside
28 analysts
$47.00
27.15% Upside
 +81.3% ·
ARWR
Arrowhead Pharmaceuticals
 Jul 02, 2021 BUY Strong Buy
+10.1% avg upside
28 analysts
$95.00
44.09% Upside
 -43.0% ·
FTH
Faeth Therapeutics
 Jun 29, 2021 BUY Strong Buy
+71.9% avg upside
20 analysts
$14.00
49.91% Downside
 -75.4% ·
NMTRQ
9 Meters Biopharma
 Jun 04, 2021 BUY Buy
+3234374900.0% avg upside
11 analysts
$3.00
299999900.02% Upside
 · ·
PLRX
Pliant Therapeutics
 Apr 05, 2021 BUY Buy
+1960.5% avg upside
21 analysts
$52.00
4714.87% Upside
 · ·
IDYA
IDEAYA Biosciences
 Mar 24, 2021 BUY Strong Buy
+31.2% avg upside
29 analysts
$33.00
10.06% Downside
 -45.3% ·
CHRS
Coherus Biosciences
 Feb 25, 2021 BUY Buy
+994.9% avg upside
18 analysts
$27.00
2289.38% Upside
 -23.1% ·
STTK
Shattuck Labs
 Jan 20, 2021 BUY Strong Buy
+253.5% avg upside
16 analysts
$75.00
1135.67% Upside
 -85.9% ·
AGIO
Agios Pharma
 Dec 23, 2020 BUY Strong Buy
+90.7% avg upside
29 analysts
$65.00
99.53% Upside
 -18.2% ·
CTMX
CytomX Therapeutics
 Sep 15, 2020 HOLD Strong Buy
+299.7% avg upside
21 analysts
$8.50
214.83% Upside
 -31.2% ·
ADAPY
Adaptimmune Therapeutics
 Apr 27, 2020 BUY Hold
+9017.7% avg upside
10 analysts
$5.00
19507.85% Upside
 · ·
AVTR
Avantor
 Jun 11, 2019 BUY Buy
+4.2% avg upside
26 analysts
$21.00
37.79% Upside
 -5.3% ·
🔒 29 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Mohit Bansal — Frequently Asked Questions
How accurate are Mohit Bansal's stock ratings?
Based on the calls 13Foresight could measure, about 56% of Mohit's ratings were profitable over a one-year hold, with an average return of -0.8% per rating, or +11.7% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Mohit ranked on 13Foresight?
Mohit Bansal is currently ranked #2279 with a 2-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Mohit cover?
Mohit most recently has ratings on BNTX, AMGN, PFE, LLY, BIIB, VERA, BMRN, MRK, SMMT, ABBV, MIST, REGN and 22 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.